# Promedior

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/promedior

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.promedior.com
- Total disclosed funding: $41M
- Latest round: Series D (Feb 21, 2012)
- Investors on record: 6

## About

Promedior Inc. is a biotechnology company dedicated to developing innovative therapies to treat serious diseases, focusing primarily on regenerative medicine and immune modulation.Promedior Inc. is a biotechnology firm that specializes in developing therapies aimed at serious diseases. Established in 2006, the company is headquartered in Lexington, US. In August 2015, Promedior was acquired by Bristol-Myers Squibb Company for an upfront cash payment of USD 150 mn, with the potential for total payments to reach USD 1.25 billion. The company has completed a total of 8 deals since its founding.Promedior Inc. is focused on developing innovative therapies for serious diseases, particularly in the fields of regenerative medicine and immune modulation. The company's portfolio includes therapeutic candidates that aim to address unmet medical needs, particularly in conditions that affect immune response and tissue regeneration. By leveraging advanced technologies and research, Promedior seeks to bring forth solutions that can significantly improve patient outcomes in the healthcare sector.Promedior Inc. generates revenue through strategic partnerships and collaborations, particularly following its acquisition by Bristol-Myers Squibb Company. The financial structure of Promedior's operations will benefit from the potential total payments of USD 1.25 billion from this acquisition, which underscores the anticipated value of its therapeutic developments.Following its acquisition by Bristol-Myers Squibb, Promedior Inc. aims to leverage its innovative therapies to expand its market reach. The recent acquisition deal, completed in August 2015, provides substantial financial resources that will be utilized to develop new products and enhance research initiatives. Plans include targeting new geographical markets to increase accessibility to its therapies, with a focus on key regions over the next few years, aligning with Bristol-Myers Squibb's strategic growth objectives.

## Funding rounds

- Series D, Feb 21, 2012, $22M — HealthCare Ventures, Morgenthaler Ventures, Polaris Partners, Easton Capital Investment Group, Forbion
- Series C, Mar 1, 2010, $12M — HealthCare Ventures, Morgenthaler Ventures, Polaris Partners, Easton Capital Investment Group, Forbion
- Series A, May 1, 2006, $7M — HealthCare Ventures, Morgenthaler Ventures, Polaris Partners, Easton Capital Investment Group, Trellis Partners

## Investors

- HealthCare Ventures — Series A, Series C, Series D
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series C, Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series C, Series D
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series A, Series C, Series D
- Trellis Partners (https://capitalatlas.ai/funds/trellis-partners) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C, Series D